On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
An allotypic form of the low affinity IgG Fc receptor Fc gamma RIIa (CD32), termed low responder (LR) because of its weak reactivity with mouse (m) IgG1, interacts efficiently with human (h) IgG2. Fc gamma RIIaLR is the first known human FcR that binds this IgG subclass. In this study, we analyzed the role of Fc gamma RIIa in binding of stable hIgG-subclass dimers, and in induction of T cell mitogenesis using chimeric anti-CD3 mAb. We demonstrate that the functional polymorphism to hIgG2 is expressed on the majority of Fc gamma R-bearing peripheral blood cells: monocytes, neutrophils, and platelets. We were able to assess Fc gamma RII-mediated IgG-binding without interference of other Fc gamma R-classes, by blockade of Fc gamma RI on monocytes, and by using neutrophils of an individual deficient for the Fc gamma RIIIB gene. This study indicates as subclass specificity: hIgG3 >hIgG1,hIgG2 >> hIgG4 for Fc gamma RIIaLR and hIgG3,hIgG1 >> hIgG2 > hIgG4 for Fc gamma RIIaHR. Comparing the serum hIgG levels of individuals homozygous for the two fc gamma RIIa allotypic forms, we observed significantly lower hIgG2 serum levels in individuals expressing the hIgG2-binding LR allotypic form. This observation may implicate that Fc gamma RIIa regulates hIgG subclass production or turnover in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ravetch, J. V., & Kinet, J. P. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.002325 · Cited by 1,229
Production of hybridoma growth factor by human monocytes
Aarden, L. A., De Groot, E. R., Schaap, O. L., & Lansdorp, P. M. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171004 · Cited by 1,092
Self-citationThe T Cell Receptor/Cd3 Complex: A Dynamic Protein Ensemble
Clevers, H. (1988) · Annual Review of Immunology · doi:10.1146/annurev.immunol.6.1.629 · Cited by 791
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
Warmerdam, P. A., van de Winkel, J. G., Vlug, A., Westerdaal, N. A., & Capel, P. J. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1338 · Cited by 463
Self-citationBiology of Human Immunoglobulin G Fc Receptors
van de Winkel, J. G. J., & Anderson, C. L. (1991) · Journal of Leukocyte Biology · doi:10.1002/jlb.49.5.511 · Cited by 392
Self-citationImmune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells.
Perussia, B., Dayton, E. T., Lazarus, R., Fanning, V, & Trinchieri, G. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.4.1092 · Cited by 332
Molecular basis for a polymorphism of human Fc gamma receptor II (CD32).
Warmerdam, P. A., van de Winkel, J. G., Gosselin, E. J., & Capel, P. J. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.19 · Cited by 298
Self-citationBrooks, D. G., Qiu, W. Q., Luster, A. D., & Ravetch, J. V. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.4.1369 · Cited by 297
Organization of the Human and Mouse Low-affinity FcγR Genes: Duplication and Recombination
Qiu, W. Q., de Bruin, D., Brownstein, B. H., Pearse, R., & Ravetch, J. V. (1990) · Science · doi:10.1126/science.2139735 · Cited by 291
Cited by
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
“Binding is more efficient for the 131H (“lowresponder,” LR) variant than the 131R (“high-responder,” HR) variant (nomenclature based on differential binding to mouse IgG1, which binds the HR much better) (155).”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications
van de Winkel, J. G. J., & Capel, P. J. A. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90166-i · Cited by 692
Self-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
“Such observations were not common to the CD32a-H131R polymorphism, which is associated with greater affinity for IgG2 rather than IgG1 (Figures S5A and S5B) (Parren et al., 1992; Salmon et al., 1992).”
BackgroundBibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans.
Salmon, J. E., Millard, S., Schachter, L. A., Arnett, F. C., Ginzler, E. M., Gourley, M. F., Ramsey-Goldman, R., Peterson, M. G., & Kimberly, R. P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118552 · Cited by 469
Chung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M. K., Rolland, M., Suscovich, T. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007736 · Cited by 406
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24772 · Cited by 377
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
Structural recognition and functional activation of FcγR by innate pentraxins
Lu, J., Marnell, L. L., Marjon, K. D., Mold, C., Du Clos, T. W., & Sun, P. D. (2008) · Nature · doi:10.1038/nature07468 · Cited by 301
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
Van Sorge, N. M., Van Der Pol, W., & Van De Winkel, J. G. J. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00037.x · Cited by 294
Self-citationHezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
Self-citationClavel, C., Nogueira, L., Laurent, L., Iobagiu, C., Vincent, C., Sebbag, M., & Serre, G. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23284 · Cited by 277
Cloutier, N., Tan, S., Boudreau, L. H., Cramb, C., Subbaiah, R., Lahey, L., Albert, A., Shnayder, R., Gobezie, R., Nigrovic, P. A., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201846 · Cited by 254
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 222
Self-citationClinical significance of IgG Fc receptors and FcγR-directed immunotherapies
Deo, Y. M., Graziano, R. F., Repp, R., & van de Winkel, J. G. J. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01007-4 · Cited by 213
Self-citationFca Receptor Iia (Cd32) Polymorphism In Fulminant Meningococcal Septic
Bredius, R. G. M., Derkx, B. H. F., Fijen, C. A. P., de Wit, T. P. M., Haas, M. D., Weening, R. S., van de Winkel, J. G. J., & Out, T. A. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.4.848 · Cited by 192
Self-citationSkov, L., Beurskens, F. J., Zachariae, C. O. C., Reitamo, S., Teeling, J., Satijn, D., Knudsen, K. M., Boot, E. P. J., Hudson, D., Baadsgaard, O., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.669 · Cited by 177
Self-citationValerius, T., Repp, R., de Wit, T., Berthold, S., Platzer, E., Kalden, Jr., Gramatzki, M., & van de Winkel, J. (1993) · Blood · doi:10.1182/blood.v82.3.931.931 · Cited by 165
Self-citationThe immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases
Karsten, C. M., & Köhl, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.015 · Cited by 158
“Fc Rs are xpressed on the surface of monocytes, macrophages, dendritic ells (DC), neutrophils, natural killer (NK) and NKT cells and on cells (Boruchov et al. 2005; Dhodapkar et al. 2005; Kim et al. 006; Parren et al. 1992; van de Winkel and Capel 1993) but not n T cells (Takai 2002).”
Background
Metadata
- Authors
- Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G.
- Venue
- Journal of Clinical Investigation
- Published
- 1992-10-01
- Volume
- 90
- Issue
- 4
- Pages
- 1537-1546
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2117162099
- Cited by
- 346
- References
- 29
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.